Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
University of Zurich · University Hospital of Zurich · +23 more institutions
Indexed incrossrefdatacitepubmed
Abstract
No abstract available for this paper.
Citation impact
1,105
total citations
- FWCI
- 57.10
- Percentile
- 100%
- References
- 21
Citations per year
Authors
193Topics & keywords
Topics
Keywords
- Temozolomide
- Medicine
- Internal medicine
- Clinical endpoint
- Oncology
- Progression-free survival
- Phases of clinical research
- Clinical trial
No related works found for this paper.